Reaction Details Report a problem with these data
Target
Interleukin-1 receptor-associated kinase 4
Ligand
BDBM504489
Substrate
n/a
Meas. Tech.
Biochemical Assay
IC50
<30±n/a nM
Citation
 Crew, AP; Araujo, E Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides US Patent  US11065231 Publication Date 7/20/2021 
Target
Name:
Interleukin-1 receptor-associated kinase 4
Synonyms:
IRAK-4 | IRAK4 | IRAK4_HUMAN | Interleukin-1 receptor-associated kinase 4 (IRAK-4) | Interleukin-1 receptor-associated kinase 4 (IRAK4) | Renal carcinoma antigen NY-REN-64
Type:
Protein
Mol. Mass.:
51519.08
Organism:
Homo sapiens (Human)
Description:
Q9NWZ3
Residue:
460
Sequence:
MNKPITPSTYVRCLNVGLIRKLSDFIDPQEGWKKLAVAIKKPSGDDRYNQFHIRRFEALLQTGKSPTSELLFDWGTTNCTVGDLVDLLIQNEFFAPASLLLPDAVPKTANTLPSKEAITVQQKQMPFCDKDRTLMTPVQNLEQSYMPPDSSSPENKSLEVSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS
  
Inhibitor
Name:
BDBM504489
Synonyms:
N-(5-((4-(2-(2-(2-((2-(2,6- dioxopiperidin-3-yl)-1,3- dioxoisoindolin-4- yl)amino)ethoxy)ethoxy)ethyl) piperazin-1-yl)methyl)-1- ((1s,4s)-4- (hydroxymethyl)cyclohexyl)- 1H-benzo[d]imidazol-2-yl)- 3- (trifluoromethyl)benzamide | US11065231, Example 66
Type:
Small organic molecule
Emp. Form.:
C46H53F3N8O8
Mol. Mass.:
902.957
SMILES:
OC[C@H]1CCC(CC1)n1c(NC(=O)c2cccc(c2)C(F)(F)F)nc2cc(CN3CCN(CCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)ccc12 |r,wU:2.1,(-10.72,-6.15,;-11.75,-5.01,;-11.27,-3.54,;-12.31,-2.4,;-11.83,-.94,;-10.32,-.62,;-9.29,-1.76,;-9.77,-3.22,;-9.85,.85,;-10.75,2.09,;-12.29,2.09,;-13.06,3.43,;-12.29,4.76,;-14.6,3.43,;-15.37,2.09,;-16.91,2.09,;-17.68,3.43,;-16.91,4.76,;-15.37,4.76,;-17.68,6.1,;-16.91,7.43,;-19.22,6.1,;-18.45,7.43,;-9.85,3.34,;-8.38,2.86,;-7.05,3.63,;-5.71,2.86,;-4.38,3.63,;-3.05,2.86,;-3.05,1.32,;-1.71,.55,;-.38,1.32,;.95,.55,;2.29,1.32,;3.62,.55,;4.95,1.32,;6.29,.55,;7.62,1.32,;8.96,.55,;10.29,1.32,;11.62,.55,;12.96,1.32,;12.96,2.86,;14.29,3.63,;15.62,2.86,;15.62,1.32,;16.77,.29,;18.27,.61,;16.14,-1.11,;16.91,-2.45,;18.45,-2.45,;19.22,-3.78,;18.45,-5.11,;19.22,-6.45,;16.91,-5.11,;16.14,-3.78,;14.6,-3.78,;14.61,-.95,;13.58,-2.1,;14.29,.55,;-.38,2.86,;-1.71,3.63,;-5.71,1.32,;-7.05,.55,;-8.38,1.32,)|
Structure:
Search PDB for entries with ligand similarity: